Paul Shiby, Ohri Nitin, Velten Christian, Brodin Patrik, Mynampati Dinesh, Tomé Wolfgang, Mao Serena P H, Kabarriti Rafi, Garg Madhur, Fox Jana
Department of Radiation Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Clin Transl Radiat Oncol. 2021 Mar 29;28:79-84. doi: 10.1016/j.ctro.2021.03.003. eCollection 2021 May.
PURPOSE/OBJECTIVES: Stereotactic radiosurgery (SRS) for metastatic disease to the brain is associated with higher in-brain failures compared to whole brain radiation therapy (WBRT). Here we investigated the relationship between low-dose fall off during SRS and location of new brain lesions.
One hundred sixty-seven patients treated with single fraction or fractionated SRS for intact or resected brain metastases at our institution from January 2016 to June 2018 were reviewed. Patients with imaging findings of new brain metastases after the initial SRS were included. Patients with WBRT before SRS were excluded. MRI scans for repeat treatments were fused with initial SRS plan. New lesions were outlined on the initial SRS planning CT. The mean dose that the site of new lesions received from initial SRS was tabulated.
Thirty-eight patients met inclusion criteria. 165 new lesions were evaluated. There was a lower propensity to develop new brain lesions with increasing dose received by the regions from prior SRS, with 66%, 34%, 19%, 13%, 6%, 5%, 2% and 1% of new lesions appearing in regions that received less than 1 Gy, greater than or equal to 1, 2, 3, 4, 5, 6, and 7 Gy, respectively. Higher doses are received by smaller brain volumes during SRS. After accounting for volume, 14, 14, 11, 7, 2, 2, 1 and 1 new lesions appeared per 100 cm of brain in regions that received doses of less than 1 Gy, greater than or equal to 1, 2, 3, 4, 5, 6, and 7 Gy, respectively, from prior SRS.
We identified low dose spillage during SRS to be associated with lower incidence of new brain metastases. Validation in larger dataset or prospective study of the combination of SRS with low dose WBRT would be crucial in order to establish causality of these findings.
目的/目标:与全脑放疗(WBRT)相比,立体定向放射外科治疗(SRS)脑转移瘤时脑内失败率更高。在此,我们研究了SRS期间低剂量下降与新脑病灶位置之间的关系。
回顾了2016年1月至2018年6月在本机构接受单次分割或分次SRS治疗完整或切除的脑转移瘤的167例患者。纳入初次SRS后有新脑转移瘤影像学表现的患者。排除SRS前接受WBRT的患者。将重复治疗的MRI扫描与初始SRS计划融合。在初始SRS计划CT上勾勒出新病灶。列出新病灶部位从初始SRS接受的平均剂量。
38例患者符合纳入标准。评估了165个新病灶。随着先前SRS区域接受剂量的增加,出现新脑病灶的倾向降低,分别有66%、34%、19%、13%、6%、5%、2%和1%的新病灶出现在接受小于1 Gy、大于或等于1、2、3、4、5、6和7 Gy的区域。SRS期间较小脑体积接受较高剂量。在考虑体积后,先前SRS接受剂量小于1 Gy、大于或等于1、2、3、4、5、6和7 Gy的区域,每100 cm³脑分别出现14、14、11、7、2、2、1和1个新病灶。
我们发现SRS期间的低剂量溢出与新脑转移瘤的低发生率相关。在更大数据集或SRS与低剂量WBRT联合的前瞻性研究中进行验证对于确定这些发现的因果关系至关重要。